Patients’ compliance or adherence to therapy is what stands between health inputs (medicines) and better health outcomes (cures). With this as a rallying point, Pfizer internally launched its “Alagang Pfizer, Alagang Sulit” campaign.
Challenged by the health community’s call for the pharmaceutical industry to take an active role in ensuring patient compliance, Pfizer, globally known for its well-researched medicines, has gone out of its way to help patients people stay on therapy for as long as needed and thereby achieve better results from the treatment. Inspired by the commitment to provide “Alagang Sulit,” Pfizer, according to its medical and regulatory affairs director, Dr. Anthony Leachon, has been working with doctors in promoting patient care and compliance.
“Through our ‘Alagang Sulit’ program,” said Leachon, “we want to communicate what goes into every Pfizer medicine that a patient buys — from the clinical evidence to the assurance of quality plus patient care — that, when taken together, makes for a higher value of a Pfizer drug over other alternatives.”
“Alagang Sulit” goes beyond explaining the true value by introducing Pfizer’s system of patient management. This system involves offering benefits to Pfizer patients on Pfizer maintenance medications to improve therapy adherence.
Leachon said Pfizer believes that better outcomes will result if both doctors and patients are engaged in disease management.
“This is the value-added service that Pfizer patients receive,” he said.
To attain this goal, he said Pfizer has put three important elements in its system of patient management. This system involves offering benefits to patients on Pfizer maintenance medications to improve their adherence, building customer relationships through Pfizer’s in-house call center and providing educational materials to patients to help them understand their disease.